A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma
- IInd Department of Tuberculosis and Lung Diseases, Institute of Tuberculosis and Lung Disease in Warsaw, 181 Okólna Str., 91–520 Łódź, Poland
- Dr M Szmidt.
- Received 28 September 1998
- Revision requested 11 February 1999
- Revised 2 June 1999
- Accepted 23 June 1999
Abstract
BACKGROUND Prostaglandins of the E series and misoprostol (a stable analogue of prostaglandin E1) prevent bronchoconstriction following aspirin ingestion or inhalation in subjects with aspirin sensitive asthma. A study was undertaken to investigate the influence of misoprostol on the course of aspirin induced asthma.
METHODS A double blind, crossover, randomised, placebo controlled study was performed in 17 patients with aspirin sensitive asthma (13 women) aged 26–68 years. All subjects had aspirin sensitivity confirmed by means of oral aspirin or inhaled lysine aspirin challenge. Misoprostol (Cytotec, Searle, 800 or 1600 μg daily according to individual tolerance) or placebo were administered over a period of six weeks. Morning and evening peak expiratory flow rate (PEFR), β2 agonist use, asthma and rhinitis severity scores, and defaecation score were measured daily. At the beginning and end of each treatment period spirometric tests were performed and blood was taken for eosinophil count. Eight subjects took misoprostol at a dose of 800 μg and nine subjects at a dose of 1600 μg daily.
RESULTS No differences were seen in asthma control between misoprostol and placebo except for the rhinorrhoea score which was lower on misoprostol during the period of the study.
CONCLUSION Misoprostol in a daily dose of 800 or 1600 μg does not significantly improve asthma control in subjects with aspirin sensitive asthma.
